Evolving Treatment of Advanced Colorectal Cancer

被引：17

作者：

Cercek, Andrea ^{[1
]}

Saltz, Leonard ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Gastrointestinal Oncol Serv, New York, NY 10065 USA

来源：

CURRENT ONCOLOGY REPORTS | 2010年 / 12卷 / 03期

关键词：

FOLFOX; FOLFIRI; Bevacizumab; Cetuximab; Panitumumab; KRAS; BRAF; GROWTH-FACTOR RECEPTOR; RANDOMIZED CONTROLLED-TRIAL; PHASE-II TRIAL; 1ST-LINE TREATMENT; PLUS OXALIPLATIN; COMBINATION CHEMOTHERAPY; FINAL REPORT; IRINOTECAN; CETUXIMAB; THERAPY;

D O I：

10.1007/s11912-010-0096-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Advances in colorectal cancer treatment have led to improved outcomes for patients. A number of cytotoxic agents, alone and in combination, have shown activity. The addition of the newer, so-called "targeted" agents to standard chemotherapy drugs and regimens has also modestly improved outcomes. Progress in our knowledge and understanding of molecular pathways has led to the identification of markers critical in determining response or nonresponse to some of the targeted agents. This review discusses the available therapies in metastatic colorectal cancer and describes some of the molecular markers implicated in activity and resistance to current targeted therapies.

引用

页码：153 / 159

页数：7

共 37 条

[1] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[2] Epithelial growth factor receptor interacting agents [J].

Baselga, J ;

Albanell, J .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2002, 16 (05) :1041-+

[3]

Baselga J, 2002, ONCOLOGIST, V7, P2

[4]

Berlin J, 2006, J CLIN ONCOL, V24, p158S

[5] Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer [J].

Bokemeyer, Carsten ;

Bondarenko, Igor ;

Makhson, Anatoly ;

Hartmann, Joerg T. ;

Aparicio, Jorge ;

de Braud, Filippo ;

Donea, Serban ;

Ludwig, Heinz ;

Schuch, Gunter ;

Stroh, Christopher ;

Loos, Anja H. ;

Zubel, Angela ;

Koralewski, Piotr .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :663-671

[6]

BOKEMEYER CBI, 2007, J CLIN ONCOL S, V18, P4035

[7]

Camp ER, 2005, CLIN CANCER RES, V11, P397

[8] Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer [J].

Cassidy, Jim ;

Clarke, Stephen ;

Diaz-Rubio, Eduardo ;

Scheithauer, Werner ;

Figer, Arie ;

Wong, Ralph ;

Koski, Sheryl ;

Lichinitser, Mikhail ;

Yang, Tsai-Shen ;

Rivera, Fernando ;

Couture, Felix ;

Sirzen, Florin ;

Saltz, Leonard .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) :2006-2012

[9] Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study [J].

Chibaudel, Benoist ;

Maindrault-Goebel, Frederique ;

Lledo, Gerard ;

Mineur, Laurent ;

Andre, Thierry ;

Bennamoun, Mostepha ;

Mabro, May ;

Artru, Pascal ;

Carola, Elisabeth ;

Flesch, Michel ;

Dupuis, Olivier ;

Colin, Philippe ;

Larsen, Annette K. ;

Afchain, Pauline ;

Tournigand, Christophe ;

Louvet, Christophe ;

de Gramont, Aimery .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5727-5733

[10] Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A Multicenter study of the Gruppo Oncologico Dell'Italia Meridionale [J].

Colucci, G ;

Gebbia, V ;

Paoletti, G ;

Giuliani, F ;

Caruso, M ;

Gebbia, N ;

Carteni, G ;

Agostara, B ;

Pezzella, G ;

Manzione, L ;

Borsellino, N ;

Misino, A ;

Romito, S ;

Durini, E ;

Cordio, S ;

Di Seri, M ;

Lopez, M ;

Maiello, E .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :4866-4875

← 1 2 3 4 →